Want to see BIOX full AI Analyst Report?
Top Page
Bioceres Crop Solutions
(NASDAQ:BIOX)
Select Model
Select Model
Rating:43Neutral
Price Target:
$0.36
▼(-13.17% Downside)
Action:Reiterated
Date:05/12/26
The score is held down primarily by sharply weakened profitability and elevated leverage, reinforced by an earnings-call backdrop of falling revenues, negative EBITDA, litigation/debt-acceleration risk and limited liquidity. Offsetting factors are improved operating/free cash flow and some near-term technical stabilization, but the longer-term trend and loss-making profile remain key constraints.
Positive Factors
Strong cash generation
Sustained positive operating and free cash flow provides durable internal funding for operations, working-capital needs and liability management. Over 2–6 months this supports ongoing debt reprofiling and working-capital improvements without reliance on dilutive equity issuance.
Negative Factors
Elevated leverage & limited liquidity
High leverage and a thin cash cushion materially constrain financial flexibility. With substantial short-term classified debt and limited cash, the company faces refinancing and interest-coverage pressure that can restrict investment, slow recovery and amplify creditor influence over strategy.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong cash generation
Sustained positive operating and free cash flow provides durable internal funding for operations, working-capital needs and liability management. Over 2–6 months this supports ongoing debt reprofiling and working-capital improvements without reliance on dilutive equity issuance.
Read all positive factors
Bioceres Crop Solutions Key Performance Indicators (KPIs)
Any
Revenue by Segment
Shows how much revenue each business segment contributes, highlighting areas of strength and potential growth within Bioceres Crop Solutions' diverse operations.
Shows how much revenue each business segment contributes, highlighting areas of strength and potential growth within Bioceres Crop Solutions' diverse operations.
Data provided by:
The Fly
The FlyBioceres Crop Solutions (BIOX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$27.07M
Dividend YieldN/A
Average Volume (3M)374.08K
Price to Earnings (P/E)―
Beta (1Y)1.13
Revenue Growth-26.10%
EPS Growth14.85%
CountryUS
Employees751
SectorBasic Materials
Sector Strength58
IndustryAgricultural Inputs
Share Statistics
EPS (TTM)-3.89
Shares Outstanding63,228,237
10 Day Avg. Volume159,016
30 Day Avg. Volume374,077
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.07
Price to Sales (P/S)0.85
P/FCF Ratio8.00
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.05
Revenue Forecast (FY)$378.70M
Bioceres Crop Solutions Business Overview & Revenue Model
Company Description
Bioceres Crop Solutions Corp. (BIOX) is a company dedicated to enhancing agricultural output through a diverse range of solutions. Its operations are organized into three principal divisions. The Seed and Integrated Products segment is responsible...
How the Company Makes Money
Bioceres Crop Solutions makes money by selling agricultural input products and related technologies to growers and channel partners (e.g., distributors, retailers, and seed companies). Its revenue model is primarily product-based, with key revenue...
Bioceres Crop Solutions Earnings Call Summary
Earnings Call Date:Sep 14, 2026
(Q4-2026)
| % Change Since: |
Next Earnings Date:Nov 17, 2026
Earnings Call Sentiment Neutral
The call reflected a mixed outlook. Management highlighted fourth-quarter revenue stabilization, positive adjusted EBITDA, substantial cost reductions, improved performance in several core product categories, and progress on debt maturity management and strategic simplification. However, fiscal-year revenue, gross profit, margins, and adjusted EBITDA declined, while creditor litigation, high net financial debt, inventory obsolescence, and weakness in parts of the Seeds, Crop Protection, and inoculant businesses remained significant challenges.Positive Updates
Fourth-Quarter Revenue Stabilized
Fourth-quarter revenue from continuing operations was $55.9 million, slightly above $55.4 million in the prior year, with improved performance across several core product categories.
Negative Updates
Challenging Fiscal Year and Ongoing Litigation
Management described fiscal year 2026 as challenging, citing ongoing litigation with certain creditors and the business consequences arising from those disputes.
Read all updates
Q4-2026 Updates
Positive
Negative
Fourth-Quarter Revenue Stabilized
Fourth-quarter revenue from continuing operations was $55.9 million, slightly above $55.4 million in the prior year, with improved performance across several core product categories.
Read all positive updates
Company Guidance
For fiscal year 2027 and beyond, Bioceres is targeting about 40% gross margins by focusing growth on higher quality core revenue streams particularly in Brazil and simplifying the product portfolio to focus on the most valuable and value accretive SKUs; it is also targeting a combined 23% total SG&A as a percent of revenues for fiscal year 2028, while continuing to explore further efficiencies on the OpEx front and noncore asset monetization opportunities, maintaining cost and working capital discipline, and actively addressing the company's capital structure and liquidity position.Bioceres Crop Solutions Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
33
Negative
Cash Flow
58
Neutral
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 263.68M | 333.34M | 464.83M | 419.45M | 328.46M | 206.70M |
| Gross Profit | 96.80M | 128.15M | 181.59M | 180.25M | 126.44M | 90.88M |
| EBITDA | -20.12M | -9.76M | 55.45M | 72.38M | 47.91M | 43.70M |
| Net Income | -250.55M | -55.42M | 3.24M | 18.78M | -7.20M | -6.87M |
Balance Sheet | ||||||
| Total Assets | 529.60M | 763.65M | 852.55M | 818.06M | 518.22M | 394.59M |
| Cash, Cash Equivalents and Short-Term Investments | 14.90M | 34.74M | 56.17M | 60.05M | 38.61M | 46.78M |
| Total Debt | 240.00M | 276.61M | 270.95M | 257.41M | 169.79M | 174.58M |
| Total Liabilities | 439.70M | 468.43M | 501.17M | 487.56M | 359.92M | 304.30M |
| Stockholders Equity | 63.80M | 262.81M | 315.30M | 298.85M | 127.61M | 67.74M |
Cash Flow | ||||||
| Free Cash Flow | 54.77M | 35.30M | 18.93M | -19.97M | -26.51M | -20.13M |
| Operating Cash Flow | 58.53M | 49.91M | 41.72M | 2.59M | -17.52M | -6.21M |
| Investing Cash Flow | -2.58M | -6.13M | -28.73M | -25.73M | 2.90M | -8.31M |
| Financing Cash Flow | -72.41M | -50.71M | -10.06M | 32.95M | 14.82M | 7.36M |
Bioceres Crop Solutions Technical Analysis
Negative
0.41
Price Trends
0.38
Positive
0.41
Negative
0.66
Negative
Market Momentum
<0.01
Positive
46.82
Neutral
26.29
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BIOX, the sentiment is Negative. The current price of 0.41 is below the 20-day moving average (MA) of 0.42, above the 50-day MA of 0.38, and below the 200-day MA of 0.66, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 46.82 is Neutral, neither overbought nor oversold. The STOCH value of 26.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BIOX.
Bioceres Crop Solutions Risk Analysis
Bioceres Crop Solutions disclosed 68 risk factors in its most recent earnings report. Bioceres Crop Solutions reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
Certain of the Rizobacter shares we own are subject to a judicial injunction that, if decided unfavorably to us, would require us to surrender part of our interest in Rizobacter thereby reducing our equity interest in Rizobacter. Q2, 2024
2.
The disposition or sale of our ordinary shares may be subject to taxation in Argentina. Q2, 2024
3.
Our share repurchase program may reduce liquidity. Q2, 2024
Bioceres Crop Solutions Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
45 Neutral | $12.45M | -1.05 | 79.78% | ― | -25.50% | -905.27% | |
44 Neutral | $66.08M | -1.20 | -27.83% | 1.36% | -3.54% | 56.67% | |
43 Neutral | $27.07M | -0.11 | -216.09% | ― | -26.10% | 14.85% | |
42 Neutral | $40.80M | -3.29 | -58.30% | ― | 17.50% | 24.63% | |
39 Underperform | $1.08M | -0.05 | -339.85% | ― | -12.24% | 17.56% |
* Basic Materials Sector Average
BIOX
Bioceres Crop Solutions
0.39
-1.42
-78.67%
AVD
American Vanguard
2.13
-3.48
-62.03%
SEED
Origin Agritech
0.96
-0.20
-17.67%
RKDA
Arcadia Biosciences
0.46
-3.04
-86.86%
BHST
BioHarvest Sciences
1.66
-7.34
-81.56%
Bioceres Crop Solutions Corporate Events
Bioceres Crop Solutions Revises Q3 Results and Faces Adverse Court Ruling in Noteholder Dispute
Jun 22, 2026
Bioceres Crop Solutions updated its fiscal third-quarter 2026 results on June 19 after recording an additional provision of about $3.4 million under IAS 37 tied to contingent payments from past acquisitions, an adjustment that did not affect reven...
Bioceres Subsidiary Rizobacter Completes US$42.7 Million Note Exchange to Extend Debt Maturities
Jun 1, 2026
On May 29, 2026, Rizobacter Argentina, a subsidiary of Bioceres Crop Solutions, announced it had successfully completed an exchange offer and consent solicitation for several series of its outstanding notes. The offer secured participation from ho...
Bioceres Crop Solutions Posts 3Q 2026 Loss as Revenues Slide During Post–Pro Farm Restructuring
May 12, 2026
Bioceres Crop Solutions reported fiscal third-quarter 2026 results on May 11, 2026, with revenues from continuing operations falling 23% year over year to $39.4 million and gross profit down 30% to $12.7 million. The company posted a net loss of $...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.